Welcome to our dedicated page for CUMBERLAND PHARMACEUTICALS SEC filings (Ticker: CPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cumberland Pharmaceuticals Inc. filings document a specialty pharmaceutical issuer with branded prescription products and clinical-development programs. The company's 8-K reports cover operating and financial results, FDA and clinical regulatory updates, material agreements, credit-facility amendments, capital-structure disclosures and other material events tied to its pharmaceutical portfolio.
Proxy materials and annual-meeting reports disclose board elections, auditor ratification, advisory compensation votes, executive compensation, beneficial ownership, corporate governance and shareholder proposal procedures. Financing-related filings describe revolving credit obligations, borrowing covenants, collateral arrangements and related debt disclosures.
Form 4 filing for Cumberland Pharmaceuticals Inc. (CPIX) details a series of open-market purchases executed by director Kenneth J. Krogulski under an existing Rule 10b5-1 trading plan adopted on 14 Nov 2024.
- Transaction window: 2 Jun 2025 – 30 Jun 2025 (20 trading days).
- Shares acquired: 935 common shares (19 trades of 45 shares each and one trade of 80 shares).
- Total cost basis: purchase prices ranged from $2.60 – $6.00 per share, indicating declining market prices over the period.
- Ownership change: holdings rose from 285,743 to 286,633 shares, a 0.3% increase.
- Transaction code “P” confirms open-market purchases; the “V” footnote references execution under the 10b5-1 plan.
No derivative securities were reported, and there were no dispositions. The filing is routine in nature and does not announce any corporate events, earnings data, or material changes beyond the incremental insider accumulation.